CLINICAL FEATURES OF TREATED AND UNTREATED TYPE 1 IDIOPATHIC MACULAR TELANGIECTASIA WITHOUT THE OCCURRENCE OF SECONDARY CHOROIDAL NEOVASCULARIZATION FOLLOWED FOR 2 YEARS IN JAPANESE PATIENTS

Autor: Mamoru Kobayashi, Akitaka Tsujikawa, Ayana Yamashita, Chieko Shiragami, Yukari Takasago, Aoi Ono, Rie Osaka
Jazyk: angličtina
Rok vydání: 2017
Předmět:
0301 basic medicine
Male
intravitreal bevacizumab
Visual acuity
Time Factors
genetic structures
Visual Acuity
Angiogenesis Inhibitors
chemistry.chemical_compound
0302 clinical medicine
Japan
Occlusion
Macula Lutea
Original Study
Fluorescein Angiography
Telangiectasia
Macular telangiectasia
Laser Coagulation
Incidence
General Medicine
Bevacizumab
Choroidal neovascularization
Treatment Outcome
retinal vein occlusion
Intravitreal Injections
Female
Telangiectasia
Hereditary Hemorrhagic
Type 1 idiopathic macular telangiectasia
medicine.symptom
Tomography
Optical Coherence
medicine.medical_specialty
Retinal Vein
laser photocoagulation
intravitreal anti-vascular endothelial growth factor
03 medical and health sciences
Ophthalmology
medicine
Humans
Macular edema
vascular permeability
Aged
Retrospective Studies
macular edema
business.industry
Choroid
Retinal
medicine.disease
Choroidal Neovascularization
eye diseases
retinal macroaneurysm
030104 developmental biology
chemistry
030221 ophthalmology & optometry
sense organs
business
Follow-Up Studies
Zdroj: Retina (Philadelphia, Pa.)
ISSN: 1539-2864
0275-004X
Popis: Treatment with laser photocoagulation and/or intravitreal bevacizumab was effective at treating Type 1 idiopathic macular telangiectasia. The mean visual acuity was maintained from baseline. The mean central retinal thickness of eyes treated with intravitreal bevacizumab monotherapy, and intravitreal bevacizumab followed by laser photocoagulation, was significantly reduced. However, 36.7% of idiopathic macular telangiectasia eyes did not require treatment over a 2-year follow-up.
Purpose: To evaluate the clinical features of Type 1 idiopathic macular telangiectasia (IMT) followed up for 2 years. Methods: Forty-nine patients with unilateral Type 1 IMT were examined. Thirty-one IMT eyes were treated with direct laser photocoagulation and/or intravitreal bevacizumab; the remaining 18 eyes, with good vision or slight macular edema, were untreated. Changes in best-corrected visual acuity and central retinal thickness between baseline and 24 months after the initial visit were examined. Results: Of 49 eyes, nine were treated with direct laser photocoagulation, 12 with laser photocoagulation and intravitreal bevacizumab, 10 with intravitreal bevacizumab monotherapy, whereas 18 did not receive any treatment. The mean logarithm of the minimum angle of resolution best-corrected visual acuity was 0.20 ± 0.19 (median, 20/29) and 0.13 ± 0.22 (median, 20/25) at baseline and 24 months, respectively (P = 0.023). The mean central retinal thickness was 375.0 ± 94.5 μm and 315.3 ± 78.5 μm at baseline and 24 months, respectively (P < 0.001). Retinal vein occlusion and retinal macroaneurysm occurred in six eyes and one eye, respectively, during follow-up. Conclusion: Treatment with laser photocoagulation and/or intravitreal bevacizumab may be effective for Type 1 IMT, 36.7% of IMT eyes required no treatment over a 2-year follow-up, and other retinal vascular events were not uncommon.
Databáze: OpenAIRE
Externí odkaz: